Action Required: Password Reset on Next Login
As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.
To reset your password, please visit the Reset Password page.
We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Aug 30, 2024
Discovery & Translation
Science Spotlight: Roche’s intestinal immuno-organoids, cytokine METRNL’s role in tumors, and more
BioCentury’s roundup of translational innovations
BioCentury | Feb 21, 2024
Deals
Deal report: Astellas taps Kelonia for CAR Ts, Aurinia fails to find buyer, and more
Plus: Xoma-Kinnate, Almirall-Novo, Intellia-ReCode, Roche-Repare and more
BioCentury | Jan 14, 2023
Discovery & Translation
Ubiquitin-regulation for tauopathies; plus Regeneron’s IL2RG mAb for T cell-driven disease and more
BioCentury’s round-up of translational news
BioCentury | Jan 6, 2023
Product Development
Kornowski shifts gears at Boston Pharma, sets NASH program as top priority
Ex-Roche exec refines focus, decides what to keep and commercialize vs. what to partner out
BioCentury | Dec 22, 2021
Product Development
PD-1’s new narrative – a bonanza of innovation
Half the field is stuck in first gear, but a wealth of bispecifics, novel technologies are bringing new energy
BioCentury | Dec 3, 2021
Distillery Therapeutics
An mRNA vaccine for Lyme disease based on tick salivary proteins
BioCentury | Mar 25, 2021
Emerging Company Profile
Asher Bio: aiming cytokine therapies at specific immune cells
Emerging Company Profile: Asher Bio engineering cytokine specificity with Third Rock-led $55 million series A
BioCentury | Jan 6, 2021
Finance
Senti banks $105M series B as Bayer continues to show enthusiasm for gene and cell therapy biotechs
Biotech has aligned its internal focus on CAR NKs, but may partner elsewhere
BioCentury | Mar 4, 2020
Management Tracks
Karp, Ghosh depart Biogen; plus Exelixis, Senti, Applied Therapeutics, Oncopeptides, Acacia and more
BioCentury | Nov 5, 2019
Product Development
Senti taps tumor-homing MSCs for lead engineered immunotherapy
Why synthetic bio company Senti chose MSCs expressing IL-12 and IL-21 as its lead cancer program
Items per page:
1 - 10 of 89